In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...

Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

As medicine continues to progress toward personalized medicine, targeted therapy methodologies show promise to improve ...

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells.

Olaparib improved invasive disease-free survival, distant disease-free survival, and overall survival in high-risk ...

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

With a projected Compound Annual Growth Rate (CAGR) of $% during the forecast period (2022-2028), the US AML market is well-positioned for substantial progression, underpinned by the convergence of ...